Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC.
Journal: JTO clinical and research reports
Published: February 06, 2025
Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy.
Journal: Clinical lung cancer
Published: August 28, 2024
Electronic Medical Record-Based Nudge Intervention to Increase Comprehensive Molecular Genotyping in Patients With Metastatic Non-Small Cell Lung Cancer: Results From a Prospective Clinical Trial.
Journal: JCO oncology practice
Published: July 03, 2024
Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation.
Journal: Clinical lung cancer
Published: September 03, 2023
Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Journal: JCO precision oncology
Published: July 27, 2023
Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System.
Journal: Clinical lung cancer
Published: February 13, 2023
Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: July 22, 2016
Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 19, 2016
Showing 1-8 of 8
Last Updated: 09/26/2026